Media Coverage

[Analytical Cannabis] Inside the ACI’s CBD Safety Trial

The UK’s CBD industry is about to hit a crossroads. In just under five months’ time, every CBD company in the country will fall on one side of a new divide: those that have submitted a novel foods application with the country’s Food Standards Agency (FSA), and those that have not. To learn more about these time constraints and just what a CBD toxicology is, Analytical Cannabis spoke with Dr Paul Duffy, the ACI’s lead toxicologist.

[Analytical Cannabis] Proving CBD’s Safety in the UK

To find out more about ACI’s safety studies, the future of CBD in the UK, and what it takes to pass a novel foods assessment, Analytical Cannabis caught up with the ACI’s regulatory lead, Dr Parveen Bhatarah.

[EU Today] UK CBD Industry Going Strong Despite Ongoing Setbacks

Although Covid-19 continues to have a profoundly negative effect on the UK’s economy, some businesses have seen growth. One market that appears to be doing particularly well is cannabidiol (CBD): the beneficial, non-intoxicating cannabis compound.

[Analytical Cannabis] The ACI Adds 16 CBD Companies to Its CBD Toxicity Trial

Sixteen CBD companies have signed up to a UK trial that will help determine the toxicity and safety of the popular cannabis compound.

The study, which has been organized by the UK’s Association for the Cannabinoid Industry (ACI), will involve 90-day-long tests on rodents to assess how CBD affects the liver, if it promotes drowsiness, and how it may interact with other drugs.

[Canex] UK CBD Industry Body Announce Landmark Safety Study Consortia

Today, the Association for the Cannabinoid Industry (ACI), in partnership with Advanced Development and Safety Laboratory (ADSL), is announcing a landmark study with a consortium of CBD companies to build a sustainable, safe, and fully compliant industry in the UK.

[New Food Magazine] Plans announced for creation of safe, sustainable CBD industry

Today (25 September 2020), the Association for the Cannabinoid Industry (ACI), in partnership with Advanced Development and Safety Laboratory (ADSL), has announced the launch of a landmark study with a consortium of CBD companies who are jointly committed to building a sustainable, safe and fully-compliant industry in the UK.

[New Food] The Potential Impact of Classifying CBD as a Narcotic

The European Commission is reviewing whether CBD should be classified as a narcotic. Dr Parveen Bhatarah, Head of Regulatory and Compliance Unit at The Association of the Cannabinoid Industry, explains the impact this could have on both the European and UK markets.

[Food Navigator] Love Hemp: ‘We’ve positioned ourselves as a global brand’

The CBD industry has just been dealt a potentially dangerous blow, however, with the news that the European Commission is considering classifying it as a narcotic instead of a Novel Food. While a decision won’t be made before September, it could mean that hundreds of CBD and hemp products would be unable to legally retail on the European market.

The ACI Partners with The ReLeaf CBD Podcast

The ACI is pleased to announce a partnership with The CBD Podcast by ReLeaf. The partnership commences with an interview with members of The ACI’s Regulatory and Compliance Unit, which is headed up by Dr Parveen Bhatarah. The team, which includes several new hires, ensures that our members are fully compliant with laws relating to cannabinoids.

[The Grocer] CBD will be removed from shelves next year, are you prepared?

The UK is the only market in the world where a clear regulatory framework exists for commercial adoption of CBD giving retailers the opportunity to participate in this huge market. However, they must ensure that their procurement process is able to identify the products that are fully safe and legal.

[Food Navigator] CBD body announces safety study consortium as Novel Foods crunch time looms

Ahead of the UK Food Standards Agency’s 31 March 2021 deadline for CBD products to have a validated novel foods application, the Association for the Cannabinoid Industry (ACI), which works to create a safe, legal and well-regulated CBD market in the UK, says it will lead a consortium to study the safety of CBD and decide the ingredient’s recommended daily dose.

[Health Europa] FSA provides clarification concerning CBD Novel Foods applications

The FSA clarified that several products may fall within the scope of a single CBD Novel Foods application, meaning that the finished product must be made with the applied for substance, for example, a CBD extract made by ‘X’ manufacturer, and that ‘the end use or presentation of the finished products is within the ‘uses’ identified by the application’, such as 5% CBD extract in oil.

[New Food Magazine]Crunch time for UK CBD companies

With the deadline for novel food authorisation on the horizon for UK CBD companies, Shomi Malik, Development Director at The Association for the Cannabinoid Industry (ACI), outlines the steps that must be taken to ensure dossiers meet the required standards.